Current issue
About the Journal
Scientific Council
Editorial Board
Regulatory and archival policy
Code of publishing ethics
Publisher
Information about the processing of personal data in relation to cookies and newsletter subscription
Archive
For Authors
For Reviewers
Contact
Reviewers
Annals reviewers in 2025
Annals reviewers in 2024
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
Links
Sklep Wydawnictwa SUM
Biblioteka Główna SUM
Śląski Uniwersytet Medyczny w Katowicach
Privacy policy
Accessibility statement
Reviewers
Annals reviewers in 2025
Annals reviewers in 2024
Annals reviewers in 2023
Annals reviewers in 2022
Annals reviewers in 2021
Annals reviewers in 2020
Annals reviewers in 2019
Annals reviewers in 2018
Annals reviewers in 2017
Annals reviewers in 2016
Annals reviewers in 2015
Annals reviewers in 2014
Annals reviewers in 2013
Annals reviewers in 2012
BPC-157 and the gut–brain axis: emerging links between cytoprotection and neuroregeneration
1
Department of Medical Biophysics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
Corresponding author
Barbara Pietrzyk
Katedra i Zakład Biofizyki Lekarskiej, Wydział Nauk Medycznych ŚUM, ul. Medyków 18, 40-752 Katowice
Katedra i Zakład Biofizyki Lekarskiej, Wydział Nauk Medycznych ŚUM, ul. Medyków 18, 40-752 Katowice
Ann. Acad. Med. Siles. 2026;80:42-50
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The body protection compound-157 (BPC-157) peptide modulates the gut–brain axis (GBA), affecting neural and gastrointestinal functions. Evidence suggests it may promote neuroprotection, regulate inflammation, and influence mood and cognition, with potential clinical relevance for neurodegenerative and psychiatric disorders. This review aimed to comprehensively analyze experimental and clinical data on the biological activity of BPC-157, with a particular focus on its effects on the GBA and its potential therapeutic relevance in neurodegeneration and psychiatric disease.
Material and methods:
The review authors independently screened and evaluated studies identified through medical databases, including PubMed, Scopus, and institutional repositories. Data extraction and synthesis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure methodological transparency and rigor.
Results:
The collected evidence indicates that BPC-157 exhibits pronounced cytoprotective, anti-inflammatory, and regenerative properties in preclinical models. It enhances neuronal survival, promotes angiogenesis and synaptic plasticity, and modulates key neurotransmitter systems, including dopaminergic, serotonergic, and GABAergic pathways. In animal models, BPC-157 improves motor coordination, cognitive performance, and recovery after neural injury. Preliminary human studies suggest a favorable safety profile, though clinical efficacy data remain limited.
Conclusions:
BPC-157 demonstrates broad protective and regenerative effects with potential relevance to neurological and psychiatric disorders. Its multimodal action on the GBA highlights a promising therapeutic avenue; however, well-designed clinical trials are required to confirm its efficacy, elucidate mechanisms, and establish optimal dosing strategies.
The body protection compound-157 (BPC-157) peptide modulates the gut–brain axis (GBA), affecting neural and gastrointestinal functions. Evidence suggests it may promote neuroprotection, regulate inflammation, and influence mood and cognition, with potential clinical relevance for neurodegenerative and psychiatric disorders. This review aimed to comprehensively analyze experimental and clinical data on the biological activity of BPC-157, with a particular focus on its effects on the GBA and its potential therapeutic relevance in neurodegeneration and psychiatric disease.
Material and methods:
The review authors independently screened and evaluated studies identified through medical databases, including PubMed, Scopus, and institutional repositories. Data extraction and synthesis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure methodological transparency and rigor.
Results:
The collected evidence indicates that BPC-157 exhibits pronounced cytoprotective, anti-inflammatory, and regenerative properties in preclinical models. It enhances neuronal survival, promotes angiogenesis and synaptic plasticity, and modulates key neurotransmitter systems, including dopaminergic, serotonergic, and GABAergic pathways. In animal models, BPC-157 improves motor coordination, cognitive performance, and recovery after neural injury. Preliminary human studies suggest a favorable safety profile, though clinical efficacy data remain limited.
Conclusions:
BPC-157 demonstrates broad protective and regenerative effects with potential relevance to neurological and psychiatric disorders. Its multimodal action on the GBA highlights a promising therapeutic avenue; however, well-designed clinical trials are required to confirm its efficacy, elucidate mechanisms, and establish optimal dosing strategies.
REFERENCES (58)
1.
Sikiric P, Rucman R, Turkovic B, Sever M, Klicek R, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Curr Pharm Des. 2018;24(18):1990–2001. doi: 10.2174/1381612824666180608101119.
2.
Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. doi: 10.3390/ph18020185.
3.
Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857–865. doi: 10.2174/1570159x13666160502153022.
4.
Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. doi: 10.1007/s00441-019-03016-8.
5.
Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972–1989. doi: 10.2174/1381612824666180712110447.
6.
Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am. 2017;46(1):77–89. doi: 10.1016/j.gtc.2016.09.007.
7.
Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Duran N, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482–487. doi: 10.4103/1673-5374.320969.
8.
Ilic S, Brcic I, Mester M, Filipovic M, Sever M, Klicek R, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157. Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. J Physiol Pharmacol. 2009;60 Suppl 7:107–114.
9.
Vukojević J, Vrdoljak B, Malekinušić D, Siroglavić M, Milavić M, Kolenc D, et al. The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726. doi: 10.1002/brb3.1726.
10.
Socała K, Doboszewska U, Szopa A, Serefko A, Włodarczyk M, Zielińska A, et al. The role of microbiota-gut-brain axis in neuropsychiatric and neurological disorders. Pharmacol Res. 2021; 172:105840. doi: 10.1016/j.phrs.2021.105840.
11.
Góralczyk-Bińkowska A, Szmajda-Krygier D, Kozłowska E. The Microbiota-Gut-Brain Axis in Psychiatric Disorders. Int J Mol Sci. 2022;23(19):11245. doi: 10.3390/ijms231911245.
12.
Sikiric P, Boban Blagai A, Strbe S, Beketic Oreskovic L, Oreskovic I, et al. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024;17(4):461. doi: 10.3390/ph17040461.
13.
Xue XC, Wu YJ, Gao MT, Li WG, Zhao N, Wang ZL, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032–1036. doi: 10.3748/wjg.v10.i7.1032.
14.
Vuksic T, Zoricic I, Brcic L, Sever M, Klicek R, Radic B, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768–777. doi: 10.1007/s00595-006-3498-9.
15.
Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10(1):17078. doi: 10.1038/s41598-020-74022-y.
16.
Tlak Gajger I, Smodiš Škerl MI, Šoštarić P, Šuran J, Sikirić P, Vlainić J. Physiological and Immunological Status of Adult Honeybees (Apis mellifera) Fed Sugar Syrup Supplemented with Pentadecapeptide BPC 157. Biology (Basel). 2021;10(9):891. doi: 10.3390/biology10090891.
17.
Gjurasin M, Miklic P, Zupancic B, Perovic D, Zarkovic K, Brcic L, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1–3):33–41. doi: 10.1016/j.regpep.2009.11.005.
18.
Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, et al. Beneficial effect of a novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Dig Dis Sci.1996;41(8):1604–1614. doi: 10.1007/BF02087908.
19.
Naveed M, Zhou QG, Xu C, Taleb A, Meng F, Ahmed B, et al. Gut-brain axis: A matter of concern in neuropsychiatric disorders…! Prog Neuropsychopharmacol Biol Psychiatry. 2021;104:110051. doi: 10.1016/j.pnpbp.2020.110051.
20.
Bisgaard TH, Allin KH, Keefer L, Ananthakrishnan AN, Jess T. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nat Rev Gastroenterol Hepatol. 2022;19(11):717–726. doi: 10.1038/s41575-022-00634-6.
21.
Strinic D, Belosic Halle Z, Luetic K, Nedic A, Petrovic I, Sucic M, et al. BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats. Life Sci. 2017;186:66–79. doi: 10.1016/j.lfs.2017.08.006.
22.
Perovic D, Milavic M, Dokuzovic S, Krezic I, Gojkovic S, Vranes H, et al. Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Administration of Pentadecapeptide BPC 157 Therapy. Curr Issues Mol Biol. 2022;44(5):1901–1927. doi: 10.3390/cimb44050130.
23.
Sikiric P, Marovic A, Matoz W, Anic T, Buljat G, Mikus D, et al. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. J Physiol Paris. 1999;93(6):505–512. doi: 10.1016/s0928-4257(99)00119-9.
24.
Strbe S, Smoday IM, Krezic I, Kalogjera L, Vukovic V, Zizek H, et al. Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy. Pharmaceuticals (Basel). 2023;16(6):788. doi: 10.3390/ph16060788.
25.
Tepes M, Gojkovic S, Krezic I, Zizek H, Vranes H, Madzar Z, et al. Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats. Front Pharmacol. 2021;12:718147. doi: 10.3389/fphar.2021.718147. Erratum in: Front Pharmacol. 2022;12:844785. doi: 10.3389/fphar.2021.844785.
26.
Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, et al. Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. Eur J Pharmacol. 1999;379(1):19–31. doi: 10.1016/s0014-2999(99)00486-0.
27.
Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, Staresinic M, Anic T, et al. Anxiolytic effect of BPC-157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. Acta Pharmacol Sin. 2001;22(3):225–230.
28.
Zemba Cilic A, Zemba M, Cilic M, Balenovic I, Strbe S, Ilic S, et al. Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy: BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling ‘positive-like’ symptoms of schizophrenia. Behav Brain Res. 2021;396:112919. doi: 10.1016/j.bbr.2020.112919.
29.
Jung YH, Kim H, Kim H, Kim E, Baik J, Kang H. The anti-nociceptive effect of BPC-157 on the incisional pain model in rats. J Dent Anesth Pain Med. 2022;22(2):97–105. doi: 10.17245/jdapm.2022.22.2.97.
30.
Sikiric P, Udovicic M, Barisic I, Balenovic D, Zivanovic Posilovic G, Strinic D, et al. Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy in the Heart Disturbances, Myocardial Infarction, Heart Failure, Pulmonary Hypertension, Arrhythmias, and Thrombosis Presentation. Biomedicines. 2022;10(11):2696. doi: 10.3390/biomedicines10112696.
31.
Djakovic Z, Djakovic I, Cesarec V, Madzarac G, Becejac T, Zukanovic G, et al. Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME. World J Gastroenterol. 2016;22(41):9127–9140. doi: 10.3748/wjg.v22.i41.9127.
32.
Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knees Pain. Altern Ther Health Med. 2021;27(4):8–13.
33.
Smoday IM, Petrovic I, Kalogjera L, Vranes H, Zizek H, Krezic I, et al. Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats. Biomedicines. 2022;10(6):1299. doi: 10.3390/biomedicines10061299.
34.
Sikiric P, Hahm KB, Blagaic AB, Tvrdeic A, Pavlov KH, Petrovic A, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020;14(2):153–167. doi: 10.5009/gnl18490.
35.
Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, et al. Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Dig Dis Sci. 1996;41(7):1518–1526. doi: 10.1007/BF02088582.
36.
Zlatar M, Kokot A, Vuletic LB, Masnec S, Kralj T, Perisa MM, et al. BPC 157 as a Therapy for Retinal Ischemia Induced by Retrobulbar Application of L-NAME in Rats. Front Pharmacol. 2021;12:632295. doi: 10.3389/fphar.2021.632295.
37.
Boban Blagaic A, Blagaic V, Mirt M, Jelovac N, Dodig G, Rucman R, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512(2–3):173–179. doi: 10.1016/j.ejphar.2005.02.033.
38.
Knezevic M, Gojkovic S, Krezic I, Zizek H, Malekinusic D, Vrdoljak B, et al. Occluded Superior Mesenteric Artery and Vein. Therapy with the Stable Gastric Pentadecapeptide BPC 157. Biomedicines. 2021;9(7):792. doi: 10.3390/biomedicines9070792.
39.
Kang EA, Han YM, An JM, Park YJ, Sikiric P, Kim DH, et al. BPC157 as Potential Agent Rescuing from Cancer Cachexia. Curr Pharm Des. 2018;24(18):1947–1956. doi: 10.2174/1381612824666180614082950.
40.
Perovic D, Kolenc D, Bilic V, Somun N, Drmic D, Elabjer E, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. J Orthop Surg Res. 2019;14(1):199. doi: 10.1186/s13018-019-1242-6.
41.
Lojo N, Rasic Z, Zenko Sever A, Kolenc D, Vukusic D, Drmic D, et al. Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats. PLoS One. 2016;11(9):e0162590. doi: 10.1371/journal.pone.0162590.
42.
Zemba Cilic A, Zemba M, Cilic M, Strbe S, Ilic S, Vukojevic J, et al. BPC 157, L-NAME, L-Arginine, NO-Relation, in the Suited Rat Ketamine Models Resembling “Negative-Like” Symptoms of Schizophrenia. Biomedicines. 2022;10(7):1462. doi: 10.3390/biomedicines10071462.
43.
Gojkovic S, Krezic I, Vranes H, Zizek H, Drmic D, Horvat Pavlov K, el al. BPC 157 Therapy and the Permanent Occlusion of the Superior Sagittal Sinus in Rat: Vascular Recruitment. Biomedicines. 2021;9(7):744. doi: 10.3390/biomedicines9070744.
44.
Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20–24.
45.
Du QS, Xie NZ, Huang RB. Recent development of peptide drugs and advance on theory and methodology of peptide inhibitor design. Med Chem. 2015;11(3):235–247. doi: 10.2174/1573406411666141229163355.
46.
Tan X, Liu Q, Fang Y, Yang S, Chen F, Wang J, et al. Introducing enzymatic cleavage features and transfer learning realizes accurate peptide half-life prediction across species and organs. Brief Bioinform. 2024;25(4): bbae350. doi: 10.1093/bib/bbae350.
47.
Matek D, Matek I, Staresinic E, Japjec M, Bojanic I, Boban Blagaic A, et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. doi: 10.3390/pharmaceutics17010119.
48.
Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L, et al. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats–A Review. Pharmaceuticals (Basel). 2024;17(8):1081. doi: 10.3390/ph17081081.
49.
Sikiric P, Skrtic A, Gojkovic S, Krezic I, Zizek H, Lovric E, et al. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022;28(1):23–46. doi: 10.3748/wjg.v28.i1.23.
50.
McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619. doi: 10.1007/s12178-025-09990-7.
51.
Sikiric P, Sever M, Krezic I, Vranes H, Kalogjera L, Smoday IM, et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. 2024;32(5):3119–3161. doi: 10.1007/s10787-024-01499-8.
52.
Faisan Smilevitch D, Chaput B, Grolleau JL, Rongieres M, Mansat P. Improvement in quality of life after surgery for glomus tumors of the fingers. Chir Main. 2014;33(5):330–335. doi: 10.1016/j.main.2014.07.001.
53.
Rung JP, Carlsson A, Rydén Markinhuhta K, Carlsson ML. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):827–832. doi: 10.1016/j.pnpbp.2005.03.004.
54.
Premuzic Mestrovic I, Smoday IM, Kalogjera L, Krezic I, Zizek H, Vranes H, et al. Antiarrhythmic Sotalol, Occlusion/Occlusion-like Syndrome in Rats, and Stable Gastric Pentadecapeptide BPC 157 Therapy. Pharmaceuticals (Basel). 2023;16(7):977. doi: 10.3390/ph16070977.
55.
Pevec D, Novinscak T, Brcic L, Sipos K, Jukic I, Staresinic M, et al. Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Med Sci Monit. 2010;16(3):BR81–88.
56.
Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;15563316251355551. doi: 10.1177/15563316251355551.
57.
Tian T, Jing J, Li Y, Wang Y, Deng X, Shan Y. Stable Isotope Labeling--Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS. Molecules. 2023;28(21):7345. doi: 10.3390/molecules28217345.
58.
Kolovrat M, Gojkovic S, Krezic I, Malekinusic D, Vrdoljak B, Kasnik Kovac K, et al. Pentadecapeptide BPC 157 resolves Pringle maneuver in rats, both ischemia and reperfusion. World J Hepatol. 2020;12(5):184–206. doi: 10.4254/wjh.v12.i5.184.
Share
RELATED ARTICLE
| eISSN: | 1734-025X |
The Medical University of Silesia in Katowice, as the Operator of the annales.sum.edu.pl website, processes personal data collected when visiting the website. The function of obtaining information about Users and their behavior is carried out by voluntarily entered information in forms, saving cookies in end devices, as well as by collecting web server logs, which are in the possession of the website Operator. Data, including cookies, are used to provide services in accordance with the Privacy policy.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
You can consent to the processing of data for these purposes, refuse consent or access more detailed information.
